fashion -WSS

fashion

author：Wikipedia 2025-09-30 12:18:45 - browse：34

After physically debilitating cancer treatment, Laurie Brunner encountered another medical hurdle: She had developed lymphedema that required surgery, but her BMI was over the cutoff. To receive the necessary treatment, she would have to lose weight.

“But after everything I’ve been through, my body was just not having it,” she said. So she turned to Jody Dushay, an endocrinologist at the Beth Israel Deaconess Medical Center and assistant professor of medicine at Harvard Medical School. After much discussion, the two decided that Laurie should try using weight loss medication — specifically, Wegovy — so she could become eligible for the surgery.

Before long, they had to grapple with the shortage of GLP-1 medications. “Within the first two months she had a good response,” Jody said. But “then there was the first round of shortages. … It looks like, you know, we’re heading towards that finish line. And then, ‘Oh, sorry, you can’t get it anymore.’”

On the “First Opinion Podcast,” I spoke with Jody and Laurie about how the ongoing shortages of GLP-1 medications are creating logistical and medical problems. Our conversation was based on Jody’s recent First Opinion essay, “How the Wegovy shortage is making life impossible for my patients — and for me.” We talked about the patient and provider perspective, the way stigma affects access to care, the ways weight loss medications are changing the medical system, and how the drug shortage is only part of the problem of access.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Readout LOUD podcast: Vertex data, Aduhelm, & Woodcock retires

hotspot

leisure time

WSS

FDA drug safety: Singulair case shows systemic surveillance flaws

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Allen Institute goes after foundational questions, CEO Costa says

Study suggests new cause of Down syndrome: cells linked to aging

Woodcock on FDA’s accelerated approval and her next chapter

A preacher's new calling: Diversifying neuroscience research

explore

fashion

hotspot

How to save PrEP access — and even expand it

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Medical leaders decry Supreme Court decision on affirmative action

Woodcock on FDA’s accelerated approval and her next chapter

Heart attack and stroke risk calculators need revising

New Ultima Genomics DNA sequencer can read genome for $100

After affirmative action ruling, medical educators look to 'holistic review'

Vertex non

State Dept. review finds Biden bears some blame for Afghanistan failures

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

knowledge

Vertex non

Vertex non

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Study suggests new cause of Down syndrome: cells linked to aging

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Apple Vision Pro: A first look at health apps on the new VR headset

focus

hotspot

leisure time

knowledge